keyboard_arrow_up

Companion Diagnostics growing at a CAGR of 20% during 2014 to 2020

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

MORE INFORMATION:

http://www.gosreports.com/global-companion-diagnostic-technologies-market-indication-and-geography-size-share-global-trends-company-profiles-demand-insights-analysis-research-report-opportunities-segmentation-and/

 

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technology Market Analysis

Companion diagnostics technology market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

 

Companion Diagnostics – Streamlining drug development and advancing personalized medicine

 

MORE INFORMATION:

http://www.gosreports.com/companion-diagnostics-streamlining-drug-development-and-advancing-personalized-medicine/

 

------------------

Joanna | Executive - International Business and partner Relations

E-mail: info@gosreports.com | Tel: 001-510-400-8520

Web: www.gosreports.com

________________________________________________

Gos International Inc.

Gos International Inc. is one of the leading distributors of market research reports in the world today.